Koers Diamyd Medical AB Swiss Exchange
Aandelen
SE0005162880
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- SEK | - |
Omzet 2024 * | 3 mln. 284K 266K | Omzet 2025 * | 3 mln. 284K 266K | Marktkapitalisatie | 1,34 mld. 127 mln. 119 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -133 mln. -12,6 mln. -11,79 mln. | Nettowinst (verlies) 2025 * | -165 mln. -15,64 mln. -14,63 mln. | EV/omzet 2024 * | 400 x |
Nettoliquiditeiten 2024 * | 139 mln. 13,17 mln. 12,33 mln. | Nettoliquiditeiten 2025 * | 30 mln. 2,84 mln. 2,66 mln. | EV/omzet 2025 * | 436 x |
K/w-verhouding 2024 * |
-10,1
x | K/w-verhouding 2025 * |
-8,13
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 63,2% |
Recentste transcriptie over Diamyd Medical AB
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ulf Hannelius
CEO | Chief Executive Officer | 49 | 10-04-16 |
Founder | 83 | 01-01-96 | |
Anna Styrud
DFI | Director of Finance/CFO | 63 | 01-01-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 83 | 01-01-96 | |
Director/Board Member | 63 | 01-01-12 | |
Director/Board Member | 52 | 28-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,45% | 122 mld. | |
+21,96% | 116 mld. | |
+24,57% | 27,03 mld. | |
-20,05% | 20,36 mld. | |
-16,28% | 15,91 mld. | |
-16,38% | 16,43 mld. | |
-44,35% | 15,6 mld. | |
+63,91% | 14,94 mld. | |
+2,52% | 13,59 mld. |